Skip to content
Recall Observatory FDA recall evidence

Drug product

Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.

D-0271-2021

February 10, 2021

Class II

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 87298
Status
Terminated
Classification
Class II
Quantity
50 vials
Official record key
drug-enforcement:D-0271-2021

Official wording

Reason: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Code information: Lot # 31326582B, exp. date 02/2022; Lot # 31326964B, exp. date 04/2022

Distribution pattern: Product was distributed nationwide in the USA and Puerto Rico.

Derived failure modes

  • Sterility assurance

    reason.sterility_assurance · v1.0.0

    Lack of Assurance of Sterility